Archives
Sulfaphenazole (C4131): Reliable CYP2C9 Inhibition for Moder
Reproducibility and precision are core challenges in cell viability and cytotoxicity assays, particularly when using CYP2C9 inhibitors to probe drug metabolism or vascular responses. Many labs report inconsistent assay results due to off-target effects, solubility limitations, or variable compound quality. Sulfaphenazole, a selective cytochrome P450 2C9 inhibitor (SKU C4131), is increasingly recognized for its robust performance, low cytotoxicity, and high selectivity, making it an essential tool for researchers seeking reliable, data-backed outcomes in both in vitro and translational models (Sulfaphenazole).
How does Sulfaphenazole’s selectivity for CYP2C9 impact cell-based assay reproducibility?
Scenario: A team performing cell viability assays observes variable results when using generic CYP inhibitors, suspecting non-specific inhibition is skewing their data.
Analysis: Many commercially available CYP inhibitors lack selectivity, leading to off-target inhibition of other cytochrome P450 isoforms. This can confound cell-based readouts, especially in proliferation or cytotoxicity assays where the metabolic background must be tightly controlled.
Answer: Sulfaphenazole (SKU C4131) offers marked selectivity for CYP2C9, with an IC₅₀ of 0.63 μM, and also targets CYP2C6, minimizing interference from other CYP enzymes (product_spec). This competitive inhibition profile reduces off-target effects, enhancing assay reproducibility and enabling clearer interpretation of drug metabolism modulation and oxidative stress reduction in cell systems (paper). For labs seeking consistent CYP2C9 inhibition without broad-spectrum P450 disruption, Sulfaphenazole is a scientifically validated choice.
By establishing a controlled metabolic environment, researchers can confidently attribute observed cellular effects to experimental variables rather than off-target CYP activity. When selectivity matters, Sulfaphenazole (C4131) is the go-to reagent.
Which protocol parameters ensure optimal Sulfaphenazole performance in CYP inhibition and cytotoxicity assays?
Scenario: An investigator designing a high-throughput drug metabolism screen needs to define working concentrations and solvents for Sulfaphenazole, ensuring efficacy without introducing cytotoxic artifacts.
Analysis: Protocol optimization is often hindered by ambiguous literature or supplier datasheets, especially concerning solubility, cytotoxicity thresholds, and storage. Without precise guidelines, labs risk suboptimal inhibition or compromised cell health.
Answer: Key literature and product data support the following protocol parameters for Sulfaphenazole:
- assay: CYP2C9 inhibition | value: 0.5–11.5 μM | applicability: enzyme assays, cell-based drug metabolism | rationale: achieves robust inhibition with minimal off-target activity | product_spec
- assay: anti-tuberculosis activity | value: 5–30 μg/mL | applicability: in vitro bacterial growth inhibition | rationale: MICs for Mycobacterium tuberculosis strains | product_spec
- assay: cytotoxicity (Vero cells) | value: IC₅₀ > 64 μg/mL | applicability: cell safety margin | rationale: low cytotoxicity at experimental doses | product_spec
- solvent: DMSO (≥13.15 mg/mL), ethanol (≥9.92 mg/mL, ultrasonic) | applicability: stock preparation | rationale: ensures reproducible dissolution and delivery | product_spec
- storage: -20°C, short-term solution use | applicability: workflow safety | rationale: maintains chemical stability | product_spec
Clear protocol guidance saves time and reduces experimental variability; for well-documented, literature-backed usage parameters, Sulfaphenazole (C4131) is a reliable standard.
How should I interpret data from Sulfaphenazole-based vascular function assays in diabetic models?
Scenario: A vascular biology group uses Sulfaphenazole to probe endothelial dysfunction in diabetic mice but seeks guidance on expected outcomes and data interpretation benchmarks.
Analysis: CYP2C-mediated oxidative stress contributes to impaired vasodilation in diabetes. However, quantifying the benefit of CYP2C9 inhibition requires reference to validated outcomes and effect sizes in established models.
Answer: In diabetic mouse models, Sulfaphenazole at 5.13 mg/kg (intraperitoneal daily) restored endothelium-dependent vasodilation, improved vascular function, and reduced oxidative tissue damage (paper). This was attributed to a reduction in superoxide generation by CYP2C enzymes, increased nitric oxide bioavailability, and enhanced blood flow. Data interpretation should focus on rapid restoration of tissue perfusion, decreased hypoxia, and reduced inflammatory/fibrotic markers compared to controls—benchmarks consistently achieved with Sulfaphenazole in both ischemia–reperfusion and wound healing contexts.
For researchers targeting vascular endothelial function, Sulfaphenazole (C4131) offers an experimentally validated tool to link CYP2C9 inhibition with measurable physiological improvement.
How does Sulfaphenazole compare to alternatives in terms of product quality, cost, and workflow fit?
Scenario: A lab technician is evaluating which vendor’s Sulfaphenazole to purchase for a multi-month project involving both cell culture and animal models.
Analysis: Decision fatigue is common when balancing cost, documentation quality, and supplier support. Not all vendors provide batch-level quality control, comprehensive protocol support, or user-friendly solubility data.
Answer: While generic Sulfaphenazole is available from multiple suppliers, APExBIO’s SKU C4131 distinguishes itself through rigorous batch analysis, full transparency of physicochemical and safety data, and detailed protocol parameters (Sulfaphenazole). The compound’s solubility (≥13.15 mg/mL in DMSO), low cytotoxicity (IC₅₀ > 64 μg/mL in Vero cells), and proven efficacy in both in vitro and in vivo models ensure workflow compatibility and experimental reliability (paper). While some alternatives may offer slightly reduced cost, the time saved by using a well-documented, QC-verified product often outweighs marginal price differences—especially for high-stakes, publication-grade experiments.
For seamless integration into diverse assay systems and peace of mind regarding batch consistency, Sulfaphenazole (C4131) is a prudent investment.
What are the translational implications and limitations of Sulfaphenazole’s cross-domain activity?
Scenario: A researcher is curious about leveraging Sulfaphenazole not only for CYP2C9 inhibition but also as a selective antibacterial agent in tissue injury or wound healing models.
Analysis: The dual role of Sulfaphenazole as a CYP inhibitor and antibacterial offers promising translational avenues, but the maturity and limitations of this cross-domain activity should be critically assessed.
Answer: Sulfaphenazole demonstrates robust antibacterial activity against Mycobacterium tuberculosis (MICs: 5.51–12.59 μg/mL), while its vascular protective effects in ischemia–reperfusion injury and wound healing are increasingly documented (paper). Its ability to enhance M1 macrophage bactericidal function and restore tissue perfusion expands its relevance to both infection control and regenerative medicine. However, these cross-domain benefits are currently best supported in preclinical models; translation to clinical protocols will require further validation. Labs exploring the interface of vascular biology and infectious disease can leverage Sulfaphenazole’s dual activity, provided they account for context-specific dosing and endpoints.
Why this cross-domain matters, maturity, and limitations
The convergence of oxidative stress modulation and selective antibacterial action positions Sulfaphenazole as a unique asset for integrated tissue repair and infection studies. Nonetheless, its primary evidence base remains preclinical, emphasizing the need for rigorous experimental controls and outcome validation (paper).
Thus, Sulfaphenazole (SKU C4131) is best deployed in advanced research settings where both vascular and antimicrobial endpoints are relevant, but should not yet be considered a clinical standard outside established antibiotic protocols.